Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Press Release

View printer-friendly version
Amgen Completes Acquisition of Ilypsa
Acquisition of Late-Stage Selective Phosphate Binder

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 18, 2007--Amgen (NASDAQ:AMGN) announced today the completion of its acquisition of Ilypsa, a private company developing non-absorbed drugs for renal disorders. The transaction provides Amgen with a late-stage phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on hemodialysis. The acquisition was originally announced June 4.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks
Anne McNickle, 805-447-5890 (media)
Arvind Sood, 805-447-1060 (investors)